Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 24, 2025
Oligometastatic head and neck cancer: Navigating patient trajectories and broader implicationsJuliette Thariat, Jihane Lehyanti, Pierre Boisselier, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 21, 2025
Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancerVirginie Nerich, Antoine Falcoz, Lawrence Nadin, et al.
Future Oncology (London, England)|July 13, 2023
Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summaryYungan Tao, Xu-Shan Sun, Yoann Pointreau, et al.
Bulletin Du Cancer|October 1, 2013
[Treatment of primary thyroid lymphomas]Xu Shan Sun, Jacques-Olivier Bay, Pierre-Yves Marcy, et al.
International Journal of Radiation Oncology, Biology, Physics|July 27, 2025
Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the A GORTEC 2014-04 "OMET" Randomized Phase 2 TrialPauline Maury, Yann Sayous, Ryan Marnaoui, et al.
Future Oncology (London, England)|March 27, 2018
Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTECXu Shan Sun, Cécile Michel, Emmanuel Babin, et al.
Clinical Lung Cancer|March 5, 2010
Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancerPierre-Jean Souquet, Maciej Krzakowski, Rodrig Ramlau, et al.
Clinical and Translational Radiation Oncology|June 12, 2025
A GORTEC survey on low-risk CTV-P2 delineation in head and neck cancersMichel Lapeyre, Yoann Pointreau, Marc Alfonsi, et al.
Cancers|June 29, 2019
10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score AnalysisStéphanie Servagi Vernat, Jonathan Khalifa, Xu-Shan Sun, et al.
International Journal of Radiation Oncology, Biology, Physics|December 28, 2017
Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer PatientsYungan Tao, Anne Auperin, Christian Sire, et al.
Pageof 3